Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
  • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
  • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/545—Heterocyclic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
  • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/56—Ring systems containing three or more rings
  • C07D209/58—[b]- or [c]-condensed
  • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
  • C07F9/572—Five-membered rings
  • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
  • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the present invention relates to novel prodrugs of cytotoxic agents and their therapeutic uses. More specifically, the invention relates to novel prodrugs of cytotoxic agents that are analogs of CC-1065 and which comprise both a moiety for chemical linkage to a cell binding agent and a protecting group that is cleaved in vivo.
• the prodrugs can be chemically linked to cell binding agents to provide therapeutic agents capable of being activated and released in vivo, and delivered to specific cell populations in a targeted manner.
• Cytotoxic drags such as methotrexate, daunorubicin, doxorabicin, vincristine, vinblastine, melphalan, mitomycin C, chlorambucil, calicheamicin and maytansinoids have been conjugated to a variety of murine monoclonal antibodies.
• the drug molecules were linked to the antibody molecules through an intermediary carrier molecule such as seram albumin ⁇ Garnett et al, 46 Cancer Res. 2407-2412 (1986); Ohkawa et al, 23 Cancer Immunol. Immunother. 81-86 (1986); Endo et al, 47 Cancer Res. 1076-1080 (1980) ⁇ , dextran ⁇ Hurwitz et al, 2 Appl. Biochem.
• CC-1065 is a potent anti-tumor antibiotic isolated from the culture broth of Streptomyces zelensis.
• CC-1065 is about 1000-fold more potent in vitro than are commonly used anti-cancer drugs, such as doxorubicin, methotrexate and vincristine ⁇ B.K. Bhuyan et al., Cancer Res., 42, 3532- 3537 (1982) ⁇ .
• CC-1065 Compound 1, FIG. 1A
• the structure of CC-1065 has been determined by x-ray crystallography ⁇ Martin, D. G. et al, 33 J. Antibiotics 902-903 (1980), and Chidester, C. G., et al, 103 J. Am. Chem. Soc. 7629-7635 (1981) ⁇ .
• the CC-1065 molecule consists of 3 substituted pyrroloindole moieties linked by amide bonds.
• the "A" subunit has a cyclopropyl ring containing the only asymmetric carbons in the molecule.
• the cytotoxic potency of CC-1065 has been correlated with its alkylating activity and its DNA-binding or DNA-intercalating activity. These two activities reside in separate parts of the molecule.
• the alkylating activity is contained in the cyclopropapyrroloindole (CPI) subunit and the DNA-binding activity resides in the two pyrroloindole subunits (FIG. 1A).
• CC-1065 has certain attractive features as a cytotoxic agent, it has limitations in therapeutic use.
• Administration of CC-1065 to mice caused a delayed hepatotoxicity leading to mortality on day 50 after a single intravenous dose of 12.5 ⁇ g/kg ⁇ V. L. Reynolds et al., J. Antibiotics, XXIX, 319-334 (1986) ⁇ .
• This has spurred efforts to develop analogs that do not cause delayed toxicity, and the synthesis of simpler analogs modeled on CC-1065 has been described ⁇ M.A. Warpehoski et al, J. Med. Chem., 31, 590-603 (1988) ⁇ .
• CPI cyclopropabenzindole
• a cyclopropabenzindole (CBI) moiety ⁇ D.L. Boger et al., J. Org. Chem., 55, 5823-5833, (1990), D.L. Boger et al., BioOrg. Med. Chem. Lett., 1, 115-120 (1991) ⁇ .
• CBI cyclopropabenzindole
• these compounds maintain the high in vitro potency of the parental drug, without causing delayed toxicity in mice.
• these compounds are alkylating agents that bind to the minor groove of DNA in a covalent manner to cause cell death.
• CC-1065 analogs can be greatly improved by changing the in vivo distribution through targeted delivery to the tumor site, resulting in lower toxicity to non-targeted tissues, and thus, lower systemic toxicity.
• conjugates of analogs and derivatives of CC-1065 with cell-binding agents that specifically target tumor cells have been described ⁇ US Patents; 5,475,092; 5,585,499; 5,846,545 ⁇ . These conjugates typically display high target-specific cytotoxicity in vitro, and exceptional anti-tumor activity in human tumor xenograft models in mice ⁇ R.V. J. Chari et al., Cancer Res., 55, 4079-4084 (1995) ⁇ .
• Cell-binding agents are typically only soluble in aqueous medium, and are usually stored in aqueous solutions. Thus, these analogs should possess sufficient water solubility to allow for efficient reaction with cell-binding agents and subsequent formulation in aqueous solution. In addition, for cell-binding agent conjugates to have a useful shelf life, it is important that CC- 1065 analogs that are linked to these cell-binding agents are stable for an extended period of time in aqueous solutions.
• CC-1065 analogs described thus far are only sparingly soluble in water. Because of the sparing solubility of CC-1065 analogs, conjugation reactions with cell-binding agents currently have to be performed in extremely dilute aqueous solutions. Therefore, these prodrugs should have enhanced water solubility as compared to the parent drags.
• CC-1065 analogs that have been described thus far are quite unstable in aqueous solutions for the following reason.
• the seco-Torm of the drug is spontaneously converted into the cyclopropyl form, which then may alkylate DNA, if present.
• the competing reaction of the cyclopropyl form with water results in opening of the cyclopropyl ring to yield the hydroxy compound, which is inactive.
• there is a need to protect the reactive portion of CC-1065 analogs in order to extend their useful life in aqueous solution for example by the development of prodrugs of CC-1065 analogs.
• prodrugs of CC-1065 analogs that are very stable upon storage in aqueous solutions.
• these prodrugs should only be converted into active drags in vivo. Once the prodrug is infused into a patient, it should preferably be efficiently converted into active drug.
• Carzelesin is a prodrug where the phenolic group in adozelesin is protected as a phenyl carbamate ⁇ L.H. Li et al., Cancer Res., 52, 4904-4913 (1992) ⁇ .
• this prodrug is too labile for therapeutic use, and also affords no increase in water solubility compared to the parental drag.
• the phenolic residue of a CC-1065 analog was glycosylated to produce a prodrug (US Patent 5,646,298).
• this prodrug is not converted into active drug in vivo, and requires the additional administration of an enzyme from a bacterial source to convert it to the cytotoxic form.
• anticancer drags unrelated to CC-1065, that have been converted into water soluble prodrugs.
• the phenolic group is protected by a 4-piperidino-piperidino carbamate. It has been reported that this protecting group confers water solubility to the drug.
• the prodrug is readily converted in vivo in humans to the active drag, presumably by the enzyme carboxylesterase, which naturally exists in human serum, tumor tissue and in some organs ⁇ A. Sparreboom, 4, Clin. Cancer Res., 2747- 2754 (1998). L.P. Rivory et al., 52, Biochem Pharmacol, 1103-1111 (1996) ⁇ .
• the anticancer drug etoposide phosphate is an example of a prodrug that has a phosphate protecting group and is rapidly converted into active drag in vivo, presumably through hydrolysis by endogenous alkaline phosphatase ⁇ S.Z. Fields et al., 1 Clin. Cancer Res., 105-111 (1995) ⁇ .
• the object of the present invention is to provide prodrugs of CC-1065 analogs, which have enhanced stability and solubility in aqueous medium.
• This and other objects have been achieved by providing prodrugs in which the phenolic group of the alkylating portion of the molecule is protected with a functionality that renders the drag stable upon storage in aqueous solution.
• the protecting group confers increased water solubility to the drag compared to an unprotected analog.
• the protecting group is readily cleaved in vivo to give the corresponding active drug.
• the phenolic substituent is preferentially protected as a piperazino carbamate, a 4-piperidino-piperidino carbamate or as a phosphate, each of which possesses a charge at physiological pH, and thus have enhanced water solubility.
• an optional polyethylene glycol spacer has been introduced into the linking group between the terminal indolyl subunit C and the cleavable linkage such as a disulfide group. The introduction of this spacer does not alter the potency of the drug.
• a more specific embodiment of the invention provides a prodrug that comprises an analog of a seco-cyclopropabenzindole-containing cytotoxic drag that has a protecting group, which enhances water solubility and stability and that can be cleaved in vivo.
• the prodrug of this specific embodiment has a first and a second subunit that are linked by an amide bond from the secondary arnino group of the pyrrole moiety of the first subunit to the C-2 carboxyl of the second subunit.
• the first subunit is shown as formula (I), and is conjugated to the second subunit, which is selected from among formulae (II)-(IX):
• R represents a linking group that provides for linkage of the prodrug to a cell binding agent, where such linkage is preferably via a disulfide bond.
• the linking group may comprise a polyethylene glycol spacer.
• R ⁇ -R 6 are each independently hydrogen, Ci-C 3 linear alkyl, methoxy, hydroxyl, primary amino, secondary amino, tertiary amino, or amido.
• R is the protecting group that can be cleaved in vivo and enhances water solubility of the cyclopropabenzindole-containing cytotoxic drag, and is preferably a piperazino carbamate, a 4- piperidino-piperidino carbamate or a phosphate.
• the prodrugs of the invention can be used in cytotoxic conjugates in which a cell binding agent is linked to one or more of the prodrags of the present invention.
• Cell binding agents include antibodies and fragments thereof, interferons, lymphokines, vitamins, hormones and growth factors. Pharmaceutical compositions containing such conjugates are also provided.
• the cytotoxic conjugates can be used in a method for treating a subject by administering an effective amount of the above pharmaceutical composition.
• many diseases may be treated either in vivo, ex vivo or in vitro.
• diseases include, for example, the treatment of many kinds of cancers, including lymphomas, leukemias, cancer of the lung, breast, colon, prostate, kidney, pancreas, and the like.
• prodrugs of CC-1065 analogs that have improved solubility and stability in aqueous solution, and which retain cytotoxicity when activated to produce an alkylating drug, and which are useful in the targeting of specific cell types by means of conjugation to a specific cell binding agent.
• FIG. 1A shows the structure of CC-1065 and its subunits A, B, and C.
• FIG. IB and FIG. 1C show the structures of two known analogs of CC-1065.
• FIG.2 shows the structures of exemplary CC-1065 analogs and prodrugs of the present invention.
• FIG.3 shows the structures of exemplary polyethylene glycol-containing prodrugs of the present invention.
• FIG.4 A and B are synthesis schemes for preparing (S)-N-[2- ⁇ (l-chloromethyl)-l,2-dihydro-5-
• FIG.5 shows schemes for the synthesis of PEGylated versions of DC1, DC2 and DC3, which are DC5, DC6 and DC7, respectively.
• FIG. 6 shows two synthetic schemes for the preparation of (S)-N-[2- ⁇ (l-chloromethyl)-l,2- dihydro-5-(phosphonoxy)-3H-benz(e)indol-3 -yl ⁇ carbonyl]- lH-indol-5-yl] -5-[(3 -mercapto- 1 - oxopropyl)-amino] - lH-indole-2-carboxamide (DC4)).
• the present inventors have found that the stability, water solubility and utility of certain CC-1065 analogs are enhanced by protection of the alkylating moiety of the analog with a suitable protecting group.
• the inventors have thereby provided prodrags of CC-1065 analogs having enhanced aqueous solubility and stability and which are further capable of linkage to cell binding agents whereby the therapeutic efficacy of such prodrags of CC-1065 analogs is improved by changing the in vivo distribution through targeted delivery of the prodrug to the tumor site, resulting in a lower toxicity to non-targeted tissues, and hence lower systemic toxicity.
• endogenous substances Upon delivery of the prodrug, endogenous substances substantially convert the prodrug to its active drag form, and, in embodiments having a cleavable linker to the cell binding agent, the active drag form of the CC-1065 analog is released, thus further enhancing its cytotoxic activity.
• the linker to the cell binding agent may be first cleaved inside the target cell to release the prodrag, followed by endogenous conversion into the active drug.
• exemplary prodrugs of CC-1065 analogs that are sec ⁇ -cyclopropabenzindole (CBI)-containing cytotoxic prodrugs comprising: (a) a first subunit of formula (I) that is protected at the phenolic hydroxyl by a protecting group to enhance stability and water solubility and which is cleaved in vivo, and (b) a second subunit having the structure represented by one of formulae (II)-(IX) and which comprises a linking group for conjugation of the prodrag to a cell binding agent.
• the linking group can contain a polyethylene glycol spacer (FIG.3). Removal of the protecting group of the prodrag produces an active form of the drug that retains the high cytotoxicity of the parent drug.
• the linker is used for conjugation to cell binding agents, preferably via a disulfide bond.
• the inventors describe the synthesis of prodrugs of CC-1065 analogs, procedures for their conjugation to monoclonal antibodies and for measurement of the in vitro cytotoxicity and specificity of such conjugates.
• the invention provides useful compounds for the preparation of therapeutic agents directed to the elimination of diseased or abnormal cells that are to be killed or lysed such as tumor cells, virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells (cells that produce auto-antibodies), activated cells (those involved in graft rejection or graft vs. host disease), or any other type of diseased or abnormal cells, while exhibiting minimal side effects.
• this invention teaches the synthesis of prodrug analogs and derivatives of CC-1065 that can be chemically linked to a cell binding agent and that maintain, upon release of the protective group, the high cytotoxicity of the parent compound CC-1065. Further, upon activation, these compounds when linked to a cell binding agent are cytotoxic to cells to which the cell binding agent binds and are much less toxic to non-target cells.
• the prodrugs according to the present invention comprise an analog of CC-1065 in which the phenolic group of the alkylating portion of the molecule is protected and the prodrug further comprises a linker capable of conjugating the prodrug to a cell binding agent.
• the prodrag may comprise a first and a second subunit that are linked via an amide bond.
• the prodrag of the CC-1065 analog has a first subunit that is a seco-CBl (cyclopropabenzindole unit) in its open chloromethyl form, wherein the first subunit has a phenolic hydroxyl that is protected by a water-soluble protecting group that can be cleaved in vivo.
• the second subunit of the prodrug of certain embodiments of the present invention comprises an analog of the combined B and C subunits of CC-1065 (FIG. 1) that are 2-carboxy-indole or 2-carboxy-benzofuran derivatives, or both, and are represented by formulae (II)-(IX).
• the B and C subunits can also carry different substituents at different positions on the indole or benzofuran rings, corresponding to positions RpR 6 of formulae (II)-(IX), and still retain potent cytotoxic activity.
• the prodrug In order to link the prodrug of the CC-1065 analog to a cell-binding agent, the prodrug must first include a moiety that allows the derivatives to be linked to a cell binding agent via a cleavable linkage such as a disulfide bond, an acid-labile group, a photo-labile group, a peptidase-labile group, or an esterase-labile group.
• the prodrag analogs are prepared so that they contain a moiety necessary to link the analog to a cell binding agent via, for example, a disulfide bond, an acid-labile group, a photo-labile group, a peptidase-labile group, or an esterase-labile group.
• the linking group can contain a polyethylene glycol spacer (FIG. 3).
• a disulfide linkage is used because the reducing environment of the targeted cell results in cleavage of the disulfide and release of the prodrug (or drag, depending on the relative sequence of cleavage of the prodrag from the cell binding agent and hydrolysis of the protecting group), with an associated increase in cytotoxicity.
• the prodrug of an analog of CC-1065 comprises first and second subunits that are covalently linked via an amide bond from the secondary amino group of the pyrrole moiety of the first subunit to the C-2 carboxy group of the second subunit having the formulae (II)-(IX).
• R represents a moiety that enables linkage of the prodrug of a CC-1065 analog to a cell binding agent.
• the linking moiety may contain a polyethylene glycol spacer. Examples include moieties that enable linkages via disulfide bond, an acid-labile group, a photo-labile group, a peptidase-labile group, or an esterase-labile group, and are well-known in the art ⁇ see, e.g., U.S. Patent 5,846,545, which is incorporated herein by reference ⁇ .
• Preferred moieties are those that enable linkage via a disulfide bond, for example a thiol (DCl, DC2, DC3, DC4, DC5, DC6, DC7) or a disulfide (DCl -SMe, DC2-SMe, DC3-SMe, DC4-SMe, DC5-SMe, DC6-SMe, DC7-Sme, see FIGS. 2-6).
• a thiol DC2, DC3, DC4, DC5, DC6, DC7
• DCl -SMe disulfide
• DC2-SMe DC2-SMe
• DC3-SMe DC4-SMe
• DC5-SMe DC6-SMe
• DC7-Sme see FIGS. 2-6.
• R can optionally further comprise a spacer region interposed between the reactive group of the linkage-enabling portion and the 2-carboxy-indole or 2- carboxy-benzofuran derivative portion.
• Preferred embodiments include NHCO(CH 2 ) m SZ, NHCOC 6 H 4 (CH 2 ) m SZ, or O(CH 2 ) m SZ, NHCO(CH 2 ) m (OCH 2 CH 2 ) precaution SZ, NHCOC 6 H 4 (CH 2 )m(OCH 2 CH 2 ) admirSZ, or O(CH 2 ) m (OCH 2 CH 2 ) n SZ wherein: Z represents H or SR 8 , wherein R 8 represents methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic, and m represents an integer of 1 to 10, n represents an integer of 4 to 1000.
• Examples of linear alkyls represented by R 8 include methyl, ethyl, propyl, butyl, pentyl and hexyl.
• Examples of branched alkyls represented by R 8 include isopropyl, isobutyl, sec-butyl, ter -butyl, isopentyl and 1-ethyl-propyl.
• Examples of cyclic alkyls represented by R 8 include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
• Examples of simple aryls represented by R 8 include phenyl and naphthyl.
• substituted aryls represented by R 8 include aryls such as phenyl or naphthyl substituted with alkyl groups, with halogens, such as Cl, Br, F, nitro groups, amino groups, sulfonic acid groups, carboxylic acid groups, hydroxy groups and alkoxy groups.
• Heterocyclics represented by R 8 are compounds wherein the heteroatoms are selected from O, N, and S, and examples include furyl, pyrrollyl, pyridyl, (e.g., a 2-substituted pyrimidine group) and thiophene.
• Most preferred embodiments of R include NHCO(CH 2 ) 2 SH and NHCO(CH 2 ) 2 SSCH 3 .
• R] to R ⁇ which maybe the same or different, independently represent hydrogen, -C3 linear alkyl, methoxy, hydroxyl, primary amino, secondary amino, tertiary amino, or amido.
• primary amino group-containing substituents are methyl amino, ethyl amino, and isopropyl amino.
• secondary amino group-containing substituents are dimethyl amino, diethyl amino, and ethyl-propyl amino.
• tertiary amino group-containing substituents are trimethyl amino, triethyl amino, and ethyl-isopropyl- methyl amino.
• amido groups include N-methyl-acetamido, N-methyl- propionamido, N-acetamido, and N-propionamido.
• R is an in vtv ⁇ -cleavable protecting group that enhances water solubility of the seco-cyclopropabenzindole-containing cytotoxic drug.
• preferred in v/vo-cleavable protecting groups are piperazino carbamate, a 4-piperidino-piperidino carbamate and a phosphate, and derivatives thereof.
• piperazino carbamate and 4-piperidino- piperidino carbamate protecting groups are enzyme-cleavable by enzymes such as carboxyl esterase, which occurs in serum and plasma.
• Phosphate protecting groups are cleavable by phosphatase enzymes such as alkaline phosphatase.
• Disulfide-containing and mercapto-containing prodrugs of CC-1065 analogs of the present invention can be evaluated for their ability to suppress proliferation of various unwanted cell lines in vitro only after they have been activated.
• phosphoryl group-containing prodrugs such as DC4
• carbamate-containing prodrugs such as DC3 and DC4
• Cell lines such as, for example, the human epidermoid carcinoma line KB, the human breast tumor line SK-BR-3, and the Burkitt's lymphoma line Namalwa can easily be used for the assessment of the cytotoxicity of these compounds.
• Cells to be evaluated can be exposed to the compounds for 24 hours and the surviving fractions of cells measured in direct assays by known methods. IC 50 values can then be calculated from the results of the assays.
• Cell binding agents may be of any kind presently known, or that become known, and include peptides and non-peptides. Generally, these can be antibodies (especially monoclonal antibodies) or a fragment of an antibody that contains at least one binding site, lymphokines, hormones, growth factors, nutrient- transport molecules (such as transferrin), or any other cell binding molecule or substance. More specific examples of cell binding agents that can be used include: monoclonal antibodies; single chain antibodies; fragments of antibodies such as Fab, Fab', F(ab') 2 and F v ⁇ Parham, 131 J. Immunol.
• Monoclonal antibody technology permits the production of extremely selective cell binding agents in the form of specific monoclonal antibodies.
• Particularly well known in the art are techniques for creating monoclonal antibodies produced by immunizing mice, rats, hamsters or any other mammal with the antigen of interest such as the intact target cell, antigens isolated from the target cell, whole virus, attenuated whole virus, and viral proteins such as viral coat proteins.
• the monoclonal antibody MY9 is a murine IgGi antibody that binds specifically to the CD33 Antigen ⁇ J.D. Griffin et al 8 Leukemia Res., 521 (1984) ⁇ and can be used if the target cells express CD33 as in the disease of acute myelogenous leukemia (AML).
• the monoclonal antibody anti-B4 is a murine IgG ls that binds to the CD 19 antigen on B cells ⁇ Nadler et al, 131 J. Immunol. 244-250 (1983) ⁇ and can be used if the target cells are B cells or diseased cells that express this antigen such as in non-Hodgkin's lymphoma or chronic lymphoblastic leukemia.
• GM-CSF which binds to myeloid cells can be used as a cell binding agent to diseased cells from acute myelogenous leukemia.
• IL-2 which binds to activated T-cells, can be used for prevention of transplant graft rejection, for therapy and prevention of graft- versus- host disease, and for the treatment of acute T-cell leukemia.
• MSH which binds to melanocytes, can be used for the treatment of melanoma.
• Conjugates of the prodrags and a cell binding agent can be formed using any techniques presently known or later developed.
• An indolyl, benzofuranyl, bis-indolyl, bis-benzofuranyl, indolyl-benzofuranyl, or benzofuranyl-indolyl derivative coupled to the seco-CBl analog can be prepared to contain a free amino group and then linked to an antibody or other cell binding agent via an acid labile linker, or by a photolabile linker.
• the prodrug compounds can be condensed with a peptide having a suitable sequence and subsequently linked to a cell binding agent to produce a peptidase labile linker.
• Cytotoxic compounds can be prepared to contain a primary hydroxyl group, which can be succinylated and linked to a cell binding agent to produce a conjugate that can be cleaved by intracellular esterases to liberate free prodrug.
• the prodrug compounds are synthesized to contain a free or protected thiol group, with or without a PEG-containing spacer, and then one or more disulfide or thiol-containing prodrags are each covalently linked to the cell binding agent via a disulfide bond.
• conjugates of the invention are conjugates of prodrugs of CC-1065 analogs with antibodies, antibody fragments, epidermal growth factor (EGF), melanocyte stimulating hormone (MSH), thyroid stimulating hormone (TSH), estrogen, estrogen analogs, androgen, and androgen analogs.
• EGF epidermal growth factor
• MSH melanocyte stimulating hormone
• TSH thyroid stimulating hormone
• estrogen estrogen analogs
• androgen androgen analogs.
• Disulfide linkers Antibody N901 which binds to the CD-56 antigen that is expressed on the surface of small cell lung cancer cells ⁇ J. D. Griffin, T. Hercend, R. Beveridge & S. F. Schlossman, J. Immunol, 130:2947 (1983) ⁇ can be used for the preparation of conjugates.
• the antibody is modified with N-succinimidyl-3-pyridyldithio propionate as previously described ⁇ J. Carlsson, H. Drevin & R. Axen, Biochem. J., 173:723 (1978) ⁇ to introduce, on the average, 4 pyridyldithio groups per antibody molecule.
• the modified antibody is reacted with the thiol-containing prodrag to produce a disulfide-linked conjugate.
• Acid-Labile Linkers Amino group-containing prodrags of the present invention can be linked to antibodies and other cell binding agents via an acid labile linker as previously described. ⁇ W. A. Blattler et al, Biochemistry 24, 1517-1524 (1985); U.S. Pat. Nos. 4,542,225, 4,569,789, 4,618,492, 4,764,368 ⁇ .
• an hydrazido group-containing prodrag of the present invention can be linked to the carbohydrate portion of antibodies and other cell binding agents via an acid labile hydrazone linker ⁇ for examples of hydrazone linkers see B. C. Laguzza et al, J. Med. Chem., 32, 548-555 (1989); R. S. Greenfield et al, Cancer Res., 50, 6600-6607 (1990) ⁇ .
• Photo-Labile Linkers Amine group containing prodrags of the present invention may be linked to antibodies and other cell binding agents via a photolabile linker as previously described ⁇ P. Senter et al, Photochemistry and Photobiology, 42, 231-237 (1985); U.S. Pat. No. 4,625,014 ⁇ .
• Peptidase-Labile Linkers Amine group containing prodrugs of the present invention may also be linked to cell binding agents via peptide spacers. It has been previously shown that short peptide spacers between drugs and macromolecular protein carriers are stable in serum but are readily hydrolyzed by intracellular peptidases ⁇ A. Trouet et al, Proc. Natl. Acad. Sci., 79, 626-629 (1982) ⁇ .
• the amino group containing containing prodrags maybe condensed with peptides using condensing agents such as l-ethyl-3-(3-dimethylaminopropyl)carbodiimide-HCl (EDC-HC1) to give a peptide derivative that can be linked to cell binding agents.
• condensing agents such as l-ethyl-3-(3-dimethylaminopropyl)carbodiimide-HCl (EDC-HC1) to give a peptide derivative that can be linked to cell binding agents.
• Esterase-Labile Linkers Prodrugs of the present invention bearing a hydroxy alkyl group may be succinylated with succinic anhydride and then linked to a cell binding agent to produce a conjugate that can be cleaved by intracellular esterases to liberate free drag. ⁇ For examples see E. Aboud-Pirak et al, Biochem Pharmacol., 38, 641-648 (1989) ⁇ .
• the conjugates made by the above methods can be purified by standard column chromatography or by HPLC.
• conjugates between monoclonal antibodies or cell binding agents and prodrugs of the present invention are those that are joined via a disulfide bond, as discussed above.
• Such cell binding conjugates are prepared by known methods such as modifying monoclonal antibodies with succinimidyl pyridyl-dithiopropionate (SPDP) ⁇ Carlsson et al, 173 Biochem. J. 723-737 (1978) ⁇ .
• SPDP succinimidyl pyridyl-dithiopropionate
• the resulting thiopyridyl group is then displaced by treatment with thiol containing prodrag to produce disulfide linked conjugates.
• Conjugates containing 1 to 10 prodrags linked via a disulfide bridge are readily prepared by this method. Conjugation by this method is fully described in U.S. Patent 5,585,499, which is incorporated by reference.
• Cytotoxicity of the prodrugs of the present invention and their conjugates with cell binding agents can be measured after cleavage of the protecting group and conversion into the active drug. Cytotoxicity to non-adherent cell lines such as Namalwa and SW2 can be measured by back-extrapolation of cell proliferation curves as described in Goldmacher et al, 135 J.
• Cytotoxicity of these compounds to adherent cell lines such as A- 375 and SCaBER can be determined by clonogenic assays as described in Goldmacher et al, 102 J. Cell Biol. 1312-1319 (1986).
• the present invention also provides a therapeutic agent for inhibiting the growth of selected cell populations comprising:
• the present invention provides a method for inhibiting the growth of selected cell populations comprising contacting a cell population or tissue suspected of containing cells from said selected cell population with a cytotoxic amount of a cytotoxic agent comprising one or more of the above-described prodrags linked to a cell binding agent.
• the cytotoxic agent is prepared as described above.
• Suitable pharmaceutically acceptable carriers, diluents, and excipients are well known and can be determined by those of skill in the art as the clinical situation warrants.
• Suitable carriers, diluents and/or excipients include: (1) Dulbecco's phosphate buffered saline, pH about 7.4, containing about 1 mg/ml to 25 mg ml human serum albumin, (2) 0.9% saline (0.9% w/v NaCl), and (3) 5% (w/v) dextrose.
• the method for inhibiting the growth of selected cell populations can be practiced in vitro, in vivo, or ex vivo.
• in vitro uses include treatments of cell cultures in order to kill all cells except for desired variants that do not express the target antigen; or to kill variants that express undesired antigen.
• the conditions of non-clinical in vitro use are readily determined by the skilled artisan.
• Examples of ex vivo uses include treatments of autologous bone marrow prior to their transplant into the same patient in order to kill diseased or malignant cells: treatments of bone marrow prior to their transplantation in order to kill competent T cells and prevent graft- versus- host-disease (GVHD).
• treatments of autologous bone marrow prior to their transplant into the same patient in order to kill diseased or malignant cells treatments of bone marrow prior to their transplantation in order to kill competent T cells and prevent graft- versus- host-disease (GVHD).
• GVHD graft- versus- host-disease
• the bone marrow cells After incubation the bone marrow cells are washed with medium containing serum and returned to the patient by i.v. infusion according to known methods. In circumstances where the patient receives other treatment such as a course of ablative chemotherapy or total-body irradiation between the time of harvest of the marrow and reinfusion of the treated cells, the treated marrow cells are stored frozen in liquid nitrogen using standard medical equipment.
• the cytotoxic agent of the invention will be supplied as solutions that are tested for sterility and for endotoxin levels or as a lyophilized solid that can be redisolved in sterile water for injection.
• suitable protocols of conjugate administration are as follows. Conjugates are given weekly for 6 weeks as an i.v. bolus. Bolus doses are given in 50 to 400 ml of normal saline to which human seram albumin (e.g. 0.5 to 1 mL of a concentrated solution of human serum albumin, 100 mg/mL) can be added. Dosages will be about 50 ⁇ g to 10 mg/kg of body weight per week, i.v.
• Examples of medical conditions that can be treated according to the in vivo or ex vivo methods of killing selected cell populations include malignancy of any type including, for example, cancer of the lung, breast, colon, prostate, kidney, pancreas, ovary, and lymphatic organs; melanomas; autoimmune diseases, such as systemic lupus, rheumatoid arthritis, and multiple sclerosis; graft rejections, such as renal transplant rejection, liver transplant rejection, lung transplant rejection, cardiac transplant rejection, and bone marrow transplant rejection; graft versus host disease; viral infections, such as CMV infection, HIV infection, AIDS, etc,; bacterial infection; and parasite infections, such as giardiasis, amoebiasis, schistosomiasis, and others as determined by one skilled in the art.
• malignancy of any type including, for example, cancer of the lung, breast, colon, prostate, kidney, pancreas, ovary, and lymphatic organs; melanomas; autoimmune diseases
• Silica gel for flash column chromatography was from Baker. Tetrahydrofuran was dried by distillation over sodium metal. Dimethylactamide and dimethylformamide were dried by distillation over calcium hydride under reduced pressure. All other solvents used were reagent grade or HPLC grade.
• DC2 (2), DC3 (3) and DC4 (4) DC5 DC6 DC7 DC8 (FIGS. 2- 6) is described herein.
• DC2, DC3 and DC4 are derived from the parent drug DCl, while DC6, DC7 and DC8 can be prepared from the pegylated parent drug DC5.
• the prodrugs DC2 and DC3 are extremely stable in aqueous solutions, and can be converted into the parent drug DCl by incubation in serum, plasma or with an enzyme such as carboxyl esterase. These drags also have enhanced water solubility as compared with DCl .
• the prodrug DC4 is also extremely stable in aqueous solutions and also soluble. Incubation of DC4 with alkaline phosphatase converts it into the parent drag DCl .
• DCl was converted to the prodrag DC4 as shown in FIG. 6.
• Treatment of DCl -SMe with dibenzylphosphate and carbon tetrachloride in the presence of base provided the intermediate 4c, while reaction of DCl -SMe with phosphorous oxychloride provide intermediate 4b.
• Removal of the benzyl protecting groups of 4c with hydrogen, with concomitant reduction of the disulfide bond provided DC4.
• Reduction of intermediate 4b with TCEP or DTT provided DC4.
• the reaction mixture was stirred under an Argon atmosphere for 3 h. Analysis by TLC showed all DCl had been consumed to form an intermediate with an Rf value of 0.45 (mobile phase of 1 :2 Acetone/Toluene).
• the reaction mixture was treated with 4-methylpiperazine (8.3 mg, 0.084 mmol), and then stirred overnight under Argon.
• the mixture was then diluted with a 1:1 (v/v) ⁇ mixture of EtOAc/T ⁇ F (15 mL) and aqueous 1 M ⁇ a ⁇ 2 PO 4 , pH 5.0 (5 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc/THF (1:1, 4 x 15 ml).
• DC4-SMe A solution of DCl-SMe (lb, 50 mg, 0.073 mmol) in a mixture of THF (5 ml), CH 3 CN (4 ml) and DMA (0.5 ml) was stirred under an atmosphere of Argon. To the mixture were

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Saccharide Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)
• Bakery Products And Manufacturing Methods Therefor (AREA)
• Seasonings (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (2)

Family

ID=29214416

Family Applications (1)

Country Status (10)

Cited By (12)

Families Citing this family (113)

Family Cites Families (17)

• 2002
  • 2002-04-05 US US10/116,053 patent/US6756397B2/en not_active Expired - Fee Related
• 2003
  • 2003-03-20 AU AU2003218062A patent/AU2003218062C1/en not_active Ceased
  • 2003-03-20 EP EP03714044A patent/EP1492526B1/en not_active Expired - Lifetime
  • 2003-03-20 AT AT03714044T patent/ATE471161T1/de not_active IP Right Cessation
  • 2003-03-20 WO PCT/US2003/007282 patent/WO2003086318A2/en not_active Ceased
  • 2003-03-20 JP JP2003583343A patent/JP2005532287A/ja active Pending
  • 2003-03-20 CA CA002480759A patent/CA2480759A1/en not_active Abandoned
  • 2003-03-20 EP EP10006198A patent/EP2238988A1/en not_active Withdrawn
  • 2003-03-20 DK DK03714044.9T patent/DK1492526T3/da active
  • 2003-03-20 DE DE60333000T patent/DE60333000D1/de not_active Expired - Lifetime
  • 2003-03-20 ES ES03714044T patent/ES2347546T3/es not_active Expired - Lifetime
  • 2003-10-27 US US10/692,856 patent/US7049316B2/en not_active Expired - Fee Related
• 2005
  • 2005-09-02 US US11/217,351 patent/US7388026B2/en not_active Expired - Fee Related
• 2007
  • 2007-01-05 US US11/649,822 patent/US7655660B2/en not_active Expired - Fee Related
• 2008
  • 2008-06-23 US US12/144,612 patent/US7655661B2/en not_active Expired - Fee Related
• 2009
  • 2009-07-17 US US12/505,175 patent/US7906545B2/en not_active Expired - Fee Related
• 2010
  • 2010-06-15 JP JP2010136274A patent/JP2010229151A/ja active Pending
  • 2010-09-20 US US12/886,230 patent/US20110008373A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events